Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard E Chaisson

Showing results (61-70 of 241) with videos related to

Pageof 25
Sort By:
Annals of Internal Medicine|April 18, 2007
Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomesJean B Nachega, Michael Hislop, David W Dowdy, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 10, 2004
Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?Fred M Gordin, David L Cohn, John P Matts, et al.
Journal of the International AIDS Society|October 19, 2020
Cost-effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in UgandaOlivia Ferguson, Youngji Jo, Jeff Pennington, et al.
AIDS (London, England)|December 4, 2004
Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavirMark S Sulkowski, Shruti H Mehta, Richard E Chaisson, et al.
Journal of Clinical Microbiology|June 11, 2010
Quantitative analysis of a urine-based assay for detection of lipoarabinomannan in patients with tuberculosisMaunank Shah, Neil A Martinson, Richard E Chaisson, et al.
Clinical Immunology (Orlando, Fla.)|August 15, 2021
Systemic DPP4/CD26 is associated with natural HIV-1 control: Implications for COVID-19 susceptibilityYashini Govender, Sharon Shalekoff, Osman Ebrahim, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 27, 2005
HIV/AIDS and antiretroviral treatment knowledge, attitudes, beliefs, and practices in HIV-infected adults in Soweto, South AfricaJean B Nachega, Dara A Lehman, Dorothy Hlatshwayo, et al.
American Journal of Epidemiology|January 6, 2006
Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapyGregory M Lucas, Michael Griswold, Kelly A Gebo, et al.
Open Forum Infectious Diseases|June 3, 2015
Risk factors for developing active tuberculosis after the treatment of latent tuberculosis in adults infected with human immunodeficiency virusKojo Amoakwa, Neil A Martinson, Lawrence H Moulton, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|February 2, 2020
The impact of bone marrow stromal antigen-2 (BST2) gene variants on HIV-1 control in black South African individualsBianca Da Costa Dias, Maria Paximadis, Neil Martinson, et al.
Pageof 25

Showing results (61-70 of 241) with videos related to

Sort By:
Pageof 25
Annals of Internal Medicine|April 18, 2007
Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomesJean B Nachega, Michael Hislop, David W Dowdy, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 10, 2004
Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?Fred M Gordin, David L Cohn, John P Matts, et al.
Journal of the International AIDS Society|October 19, 2020
Cost-effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in UgandaOlivia Ferguson, Youngji Jo, Jeff Pennington, et al.
AIDS (London, England)|December 4, 2004
Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavirMark S Sulkowski, Shruti H Mehta, Richard E Chaisson, et al.
Journal of Clinical Microbiology|June 11, 2010
Quantitative analysis of a urine-based assay for detection of lipoarabinomannan in patients with tuberculosisMaunank Shah, Neil A Martinson, Richard E Chaisson, et al.
Clinical Immunology (Orlando, Fla.)|August 15, 2021
Systemic DPP4/CD26 is associated with natural HIV-1 control: Implications for COVID-19 susceptibilityYashini Govender, Sharon Shalekoff, Osman Ebrahim, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 27, 2005
HIV/AIDS and antiretroviral treatment knowledge, attitudes, beliefs, and practices in HIV-infected adults in Soweto, South AfricaJean B Nachega, Dara A Lehman, Dorothy Hlatshwayo, et al.
American Journal of Epidemiology|January 6, 2006
Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapyGregory M Lucas, Michael Griswold, Kelly A Gebo, et al.
Open Forum Infectious Diseases|June 3, 2015
Risk factors for developing active tuberculosis after the treatment of latent tuberculosis in adults infected with human immunodeficiency virusKojo Amoakwa, Neil A Martinson, Lawrence H Moulton, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|February 2, 2020
The impact of bone marrow stromal antigen-2 (BST2) gene variants on HIV-1 control in black South African individualsBianca Da Costa Dias, Maria Paximadis, Neil Martinson, et al.
Pageof 25